Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE‐binding capacity: candidates for grass pollen‐specific immunotherapy

More than 400 million individuals are sensitized to grass pollen allergens. Group 5 allergens represent the most potent grass pollen allergens recognized by more than 80 % of grass pollen allergic patients. The aim of our study was to reduce the allergenic activity of group 5 allergens for specific immunotherapy of grass pollen allergy. Based on B‐ and T‐cell epitope mapping studies and on sequence comparison of group 5 allergens from different grasses, point mutations were introduced by site‐directed mutagenesis in highly conserved sequence domains of Lol p 5, the group 5 allergen from ryegrass. We obtained Lol p 5 mutants with low IgE‐binding capacity and reduced allergenic activity as determined by basophil histamine release and by skin prick testing in allergic patients. Circular dichroism analysis showed that these mutants exhibited an overall structural fold similar to the recombinant Lol p 5 wild‐type allergen. In addition, Lol p 5 mutants retained the ability to induce proliferation of group 5 allergen‐specific T cell lines and clones. Our results demonstrate that a few point mutations in the Lol p 5 sequence yield mutants with reduced allergenic activitythat represent potential vaccine candidates for immunotherapy of grass pollen allergy.